NCT06245629Recruiting
Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
Bortezomib-bendamustine-melphalan vs High-dose Melphalan in Autologous Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma - a Single Center Retrospective Cohort Study
Source: ClinicalTrials.gov · Last updated 29 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This project will evaluate the efficacy and safety of the conditioning regimen bortezomib-bendamustine-melphalan (BBM) in combination with autologous hematopoietic stem cell transplantation (ASCT) in relapsed multiple myeloma given from 2011 to 2018 at Uppsala University Hospital. This approach will be retrospectively compared to high dose melphalan (HDM) in the same setting in the years prior to, and following the BBM-period. Data on efficacy and safety data will be collected through systematic analysis of electronic medical records and from the Swedish Cancer Registry.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 26 Sept 2023
- Start date
- 24 Nov 2024
- Primary completion date
- 31 Mar 2025
- Lead sponsor
- Uppsala University
- Diseases
- Multiple myeloma
- NCT number
- NCT06245629
What you commit to
- Study type: Observational
- Planned participants: 100
- From 24 Nov 2024 to the primary completion date, 31 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Allogenic haematopoietic stem cell transplantation as part of first or second line therapy
- Failure to meet the minimal dataset, defined as: (date of ASCT1 and ASCT2, date of start of induction treatment for relapsed myeloma prior to ASCT2, medical records from hospitalization for ASCT2, at least one follow-up visit (unless early death before first follow-up visit), date of progression and first treatment of relapsed multiple myeloma after ASCT2.
Other
- Double (tandem) ASCT in first or second line treatment
Who the study is looking for
- Diagnosis of first relapse after previous ASCT for multiple myeloma according to the International Myeloma Working Group.
- Treated with a second ASCT (ASCT2) as part of second line treatment at UUH.
- Conditioning at ASCT2 with bortezomib-bendamustine-melphalan or high-dose melphalan only.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Akademiska sjukhuset Coordinator of this site? Confirm its status | Uppsala | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.